GlassScriptPhysician profile
James P Mcgraw
NPI 1609863927
$5,505.59
in general payments reported to CMS, 2019-2025
32 companies · $1,205 in 2025
The $1,205 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $217 · 2021: $313 · 2022: $428 · 2023: $1,144 · 2024: $1,563 · 2025: $1,205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,912.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,911.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $867.12 | 2019-2025 | |
| Amgen INC. | $814.15 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $453.24 | 2019-2025 | |
| Abbott Laboratories | $449.69 | 2021-2025 | Accent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.96 | 2021-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $377.10 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $258.34 | 2020-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $249.22 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $222.56 | 2019-2025 | Eliquis, Camzyos |
| Sanofi-Aventis U.S. LLC | $205.11 | 2019-2024 | |
| Akcea Therapeutics, INC. | $152.11 | 2019 | |
| Esperion Therapeutics, INC. | $127.23 | 2022-2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $104.28 | 2019-2024 | Farxiga |
| Kiniksa Pharmaceuticals, LTD. | $84.68 | 2023 | Arcalyst |
| Novo Nordisk INC | $76.33 | 2022-2025 | Wegovy |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $75.59 | 2023 | Inpefa |
| Scpharmaceuticals INC. | $71.70 | 2023-2024 | |
| Boston Scientific Corporation | $63.57 | 2020-2025 | Watchman Access System |
| Kiniksa Pharmaceuticals International, Plc | $61.06 | 2024 | Arcalyst |
| Heartflow, INC. | $55.81 | 2025 | |
| Siemens Medical Solutions USA, INC. | $54.56 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $48.16 | 2019 | |
| Medtronic, INC. | $44.42 | 2023 | Linq II |
| Alnylam Pharmaceuticals INC. | $38.88 | 2024-2025 | Amvuttra |
| Ge Healthcare | $24.75 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $23.43 | 2023 | Uptravi |
| Bayer Healthcare Pharmaceuticals INC. | $19.19 | 2025 | |
| Irhythm Technologies, INC. | $17.58 | 2021 | |
| Inspire Medical Systems, INC. | $17.52 | 2025 | Inspire |
| Bridgebio Pharma, INC. | $16.40 | 2025 | Attruby |
| Glaxosmithkline, LLC. | $16.14 | 2025 | Arexvy, Shingrix |
| Regeneron Healthcare Solutions, INC. | $14.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Mcgraw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.